Advertisement

Resources Needed for Risk Assessment

  • G. A. Faich
Conference paper
Part of the Health Systems Research book series (HEALTH)

Abstract

This paper addresses resource needs for assessing the risk of pharmaceutical products. My remarks are largely confined to the postapproval aspects of risk assessment and are based on lessons learned during the 6 years I have been charged with postmarketing safety monitoring at the Food and Drug Administration (FDA). There are three ingredients essential for providing resources for risk assessment:
  1. a)

    data resources,

     
  2. b)

    people, and

     
  3. c)

    money.

     

Keywords

Risk Assessment Topical Minoxidil Adverse Drug Reaction Monitoring Epidemiologic Technique Intercontinental Medical Statistics 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Faich GA, Lawson DH, Tilson HH, Walker A (1987) Clinical trials are not enough: drug development and pharmacoepidemiology. J Clin Res Drug Dev 1 (1):75–78Google Scholar
  2. 2.
    Faich GA (1986) Adverse drug reaction monitoring. N Engl J Med 314 (24): 1589–1592PubMedCrossRefGoogle Scholar
  3. 3.
    Sills JM, Faich GA, Milstien JB, Turner WM (1986) Postmarketing reporting of ADR’s to FDA: an overview of the 1985 FDA guideline. Drug Inf J 20 (2):150–156Google Scholar
  4. 4.
    Scott HD, Thacher-Renshaw A, Rosenbaum SE, Waters WJ, Green M, Andrews LG, Faich G A (1990) Physician reporting of ADR’s — Rhode Island. JAMA 263:1785–1788PubMedCrossRefGoogle Scholar
  5. 5.
    Rogers AS, Israel E, Smith C, Levine D, McBean AM, Walente C, Faich GA (1988) Physician knowledge, attitudes and behavior related to reporting adverse drug events. Arch Intern Med 148:1596–1600PubMedCrossRefGoogle Scholar
  6. 6.
    Faich GA, Stadel BV (1989) The future of automated record linkage for postmarketing surveillance: a response to Shapiro. Clin Pharmacol Ther 314:387–389CrossRefGoogle Scholar
  7. 7.
    Ray WA, Griffin MR (1989) The use of medicaid data for pharmacoepidemiology. Am J Epidemiol 129:837–849PubMedGoogle Scholar
  8. 8.
    Food and Drug Administration (1987) Studies of reported adverse effects of marketed drugs; availability of grant; request for applications. Federal Register 52 July 10:26086–26088Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • G. A. Faich

There are no affiliations available

Personalised recommendations